NCT07024030View on ClinicalTrials.gov

Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions
Prostate Cancer Patients Undergoing Radical Prostatectomy
Interventions
DRUG

0.02mg/kg

Slowly infuse intravenously 24 hours before the scheduled surgery. The investigator shall conduct near-infrared fluorescence imaging during the operation to assist with the surgery. Tissues detected with fluorescence need to be marked, and resection shall be guided by fluorescence until there is no fluorescent tissue within the surgical field.

DRUG

0.04mg/kg

Slowly infuse intravenously 24 hours before the scheduled surgery. The investigator shall conduct near-infrared fluorescence imaging during the operation to assist with the surgery. Tissues detected with fluorescence need to be marked, and resection shall be guided by fluorescence until there is no fluorescent tissue within the surgical field.

Trial Locations (1)

266031

The Affiliated Hospital of Qingdao University, Qingdao

All Listed Sponsors
lead

Haitao Niu, MD

OTHER

NCT07024030 - Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer | Biotech Hunter | Biotech Hunter